PCA3 is detectable in urine and its clinical utility was explored in several studies: the clinical sensitivity and specificity of urinary PCA3 evaluation for prostate cancer detection are 58–82% and 72–79%, respectively [380,381]. This evidence concerns the gene PCA3 and prostate carcinoma.